The Omicron variant, the latest Covid mutation that is garnering international headlines, has caused a devastating ripple effect around the world. Global authorities in the UK and EU are tightening their borders in anticipation of another Covid wave.
In the United States, New York Governor Kathy Hochul has Canceled Elective surgeries in the state cite the Omicron variant, even if the transmissibility and lethality of this latest Covid mutation are unknown. The variant is thought to have originated in Botswana and may have played a role in the rise of Covid in South Africa. Variants have been identified in Botswana, South Africa, Hong Kong and Amsterdam in the Netherlands.
Pfizer-BioNTech, newly launched sky high profits in addition to the ‘vaccine’ mandated by the government, has included a ‘relaunch in the future‘ of the Covid-19 vaccine in response to the Omicron variant. However, it seems a lesser-known pharmaceutical company, Novavax, can beat it.
Novavax said on Friday that it has “started work on a version of its COVID-19 vaccine to target the variant detected in South Africa” and “will have this vaccine ready to testing and production in the next few weeks,” Reuters report.
The company’s COVID-19 snapshot contains a real-life version of a mutant protein of the virus that cannot cause disease but can activate the immune system. “The vaccine developer says they have begun developing a specific mutant protein based on the known genetic sequence of the variant, B.1.1.529.”
A company spokesman said: “Initial work will take several weeks. “The company’s shares closed up nearly 9% on Friday.”
The report notes that Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia, followed by the Philippines.
“The company said it is on track to apply for US approval later this year,” the report continued. “It has also been submitted for approval with the European Medicines Agency as well as in Canada.”
Novavax’s statement shows the possibility of continuing the achievement of a Covid vaccine that is patented and developed ‘too fast’. Before the global outbreak of SARS-CoV-2 in December 2019, it was expected that a vaccine would take years of testing and development.
Suddenly, it took almost no time to produce a so-called “vaccine” that was essentially a prophylactic therapy that would wear off for months and require a “booster”. “. It is reminiscent of how China quickly patented a vaccine after international authorities learned of Covid-19, which the Chinese Communist Party clearly knew and kept hidden from the world. from May 2019.
The sudden appearance of Covid-19 in Wuhan before China randomly filed early COVID-19 vaccine patents. Indeed, the deployment of ‘warp speed’ would be virtually impossible, unless the Chinese had conducted research on the deadly coronavirus before the world knew about it.
National security sources said the relationship between Zhou [Yusen] and Dr. Shi[Zhengli aka the “Bat Woman”] backed by US intelligence claimed that the Wuhan Institute of Virology had engaged in a “covert military operation”.
“Zhou, who conducted the research together with the Wuhan Institute, the University of Minnesota and the New York Blood Center, was the first to file a patent for a Covid-19 vaccine on February 24 last year, according to the documents. whether by The Australian Weekend. ”
This is just five weeks after China acknowledged human-to-human transmission of the virus.
The patent owner is very impressive. “Zhou was listed as the top inventor in the ‘Military Medical Institute, PLA Academy of Military Science’ patent application,’ the report reads.
The Australian contacted a virologist, who attested that the deadline for vaccination was virtually impossible.
Nikolai Petrovsky, a medical researcher at Flinders University who is developing a Covid-19 vaccine, said that while it is technically possible to have a vaccine within this timeframe, that seems unlikely. is a “remarkable achievement”.
He said it left open the possibility that Chinese scientists were working on a vaccine before authorities openly acknowledged a coronavirus outbreak.
“This is something we have never seen before achieved, raising the question of whether this work could have started much earlier,” said Prof. Petrovsky.
The plot is thick. One of the scientists involved in the study, Zhou Yusen, was the subject of an “unknown cause of death” in May 2020 after an investigation into the origins of COVID-19 was started. The Five Eyes intelligence agency is investigating the mysterious death as part of an investigation initiated by the Biden administration.
The Wall Street Journal reported earlier that scientific researchers believe that the RNA sequence in the SARS-CoV-2 virus is almost certainly of unnatural origin.
“The CGG-CGG combination has never been found spontaneously. That means the virus’s ubiquitous method of acquiring new skills, called recombination, cannot work here,” the scientists wrote in the WSJ.
They added: “A virus cannot choose a sequence from another virus if that sequence is not present in any other virus.
One scientist working on the Omicron variant described it as “terrible”. It also has unusual properties not seen in other Covid variants.
Tom Peacock, a virologist in the Department of Infectious Diseases at Imperial College in the UK, gave the latest status of scientific research on the Omicron variant.
“Just discovered: a very small cluster of variants associated with South Africa with a very long branch length and a truly horrible Spike mutation profile including RBD – K417N, N440K, G446S, S477N, T478K, E484A, Q493K , G496S, Q498R, N501Y, Y505H (github.com/cov-lineages/p…)
Full Spike Configuration: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S478497N, T478K4, E484A, Q N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. ”
“For those interested, this has an NTD insertion at the NTD insertion hotspot (at aa214), which suggests a high probability of host origin (from the TMEM245 mRNA host),” he continued. .
“It’s worth emphasizing that this is super low right now in an area of Africa that’s pretty well sampled, but it’s very much in need of monitoring given that awful spike profile (possibly). guess this is going to be worse antigenically than anything else is about),” he added.
“One final observation – this variant contains not one but two furin cleavage site mutations – P681H (seen in Alpha, Mu, some Gamma, B.1.1.318) in combination with N679K (seen in N679K). in C.1.2 among others) – this is the first time I’ve seen two of these mutations in a single variant,” he noted.
He then provided a few updates: “[T]His lineage has now been assigned as B.1.1.529: (github.com/cov-lineages/p…)
“Update on South Africa from @Tuliodna (Who is absolutely the best person to follow for updates on this) – the bottom line is that B.1.1.529 is probably already pretty popular in SA,” he added.
Tulio de Oliveira, director of South Africa’s Center for Epidemiological Response and Innovation, told the BBC the variant had an “unusual constellation of mutations”. For example, the Delta variant has two mutations to its receptor-binding region; This variant has 10, he said.
There are also anecdotal reports of cases in people who are vaccinated and reinfected, but health officials say further investigation is needed. reported. The researchers are trying to measure the variant’s global spread, as well as see if it’s proven to be milder than the Beta and Delta variants.
Aris Katzourakis, who studies virus evolution at the University of Oxford, said: “A burning question is ‘will it reduce the effectiveness of the vaccine, because it has so many changes? “.
Moore told Nature that breakthrough infections have been reported in South Africa in people who received any of the three vaccines being used there: Johnson & Johnson, Pfizer – BioNTech and Oxford – AstraZeneca.
Ravindra Gupta, professor of clinical microbiology at the University of Cambridge, said the new variant had a high number of mutant mutations that could affect transmissibility and immune response.
“There’s a lot we don’t understand about this variant,” said Richard Lessells, an infectious disease physician at the University of KwaZulu-Natal in Durban, South Africa. “The mutation profile worries us, but now we need to do the work to understand the significance of this variant and what it means for the pandemic response.”
“We’re flying at vertical speed,” Penny Moore, a virologist at the University of the Witwatersrand in Johannesburg, South Africa, told Nature. Moore added that “at this stage, it’s too early to say anything” about anecdotal reports of reinfection and cases in vaccinated people.
The Pfizer-BioNTech vaccine has been closely monitored for the declining effectiveness of its mRNA prophylaxis, which has been marketed as a ‘vaccine’ for Covid-19 . The pharmaceutical company, whose Comirnaty vaccine is ‘fully authorized’ by the Food and Drug Administration for Covid-19 has been granted full protection liability by the Biden administration. The so-called ‘vaccine’ wears out so quickly that the Centers for Disease Control has recommended the use of a “booster”.
Novavax could soon be the next pharmaceutical company to get caught up in the Covid scam. If they can produce a vaccine within a few weeks, they could see their product used by millions of people worldwide – without anyone knowing about the side effects or even requiring more medicine. strengthen for another six months.
https://smartzune.com/as-omicron-variant-throws-world-into-chaos-one-company-suddenly-says-it-already-has-vaccine-in-testing-for-it/ As the Omicron variant throws the world into chaos, a company suddenly says it has a ‘vaccine’ to test it